FDA in the Year of COVID How FDA Tackled the Pandemic and What to Expect from FDA in 2021
Program Number
Program Date
CLE Credits
Over the past year, industries all over the world have experienced disruptions and have been forced to adapt to the COVID-19 pandemic. Notably, the Food and Drug Administration (“FDA) has been thrust to the forefront of the battle against COVID-19, and emergency use authorizations (“EUAs) and Operation Warp Speed are now hot topics. EUAs have allowed FDA to pivot and make speedy decisions that help save lives, but EUAs arent without their pitfalls. Additionally, Operation Warp Speed has been an impressive scientific endeavor, helping to bring vaccines to market in record time. As FDA has adapted quickly to the most up to date knowledge about this novel virus and changing scientific data, including real world evidence, what is in store for 2021? A new administration begins on January 20, 2020, and this new administration will bring different goals and plans for fighting COVID-19. Looking to 2021, we will see whether FDAs operations go back to their pre-pandemic normal and how FDA might continue to use real world evidence to support important regulatory decisions.
Available in States
- California
- Georgia
- New Jersey
- New York
- Texas Self Study
Program Categories
- Constitutional Law
- Consumer Protection Laws
- Covid-19
- Federal Courts
- Health Care Law
- In-House Counsel
- Pharmaceutical Law
PROGRAM CREDITS
- Areas of Professional Practice : 1 Credit
